NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Pretzel Therapeutics

Pretzel Therapeutics

Private
Waltham, MassachusettsHealthcare & Life Scienceshttps://www.pretzeltx.com/

Last Round

VC Round

Jul 11, 2025

Total Funding Raised

$72.5M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Pretzel Therapeutics is a biotechnology company developing first-in-class therapies to reverse mitochondrial dysfunction by leveraging a deep mechanistic understanding of mitochondrial biology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

mitochondrial diseasebioenergeticsPOLG diseasemitochondrial therapybiotech startupclinical-stage biotechrare disease drugsmall-molecule therapeuticsdrug discoveryclinical trialorphan drugmitochondrial dysfunctionbiopharmacellular therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Pretzel Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Pretzel Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Pretzel Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJul 11, 2025
Series ASep 12, 2022

Key People

Founding team and executive leadership

Jay Parrish

Chairman and CEO

Executive Team

Baruch Harris

Chief Operating Officer

Executive Team

Pretzel Therapeutics Investors

Notable investors and investment history

Pretzel Therapeutics investors
InvestorRounds
Vasa Angels ISeries A
GVSeries A
ARCH Venture PartnersSeries A
United Mitochondrial Disease FoundationVC Round
HealthCapSeries A
Eir VenturesSeries A
Invus OpportunitiesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 11, 2026

    PX578 data presented at the 2026 MDA Clinical & Scientific Conference.

  • Mar 11, 2026

    Presented data at the 2026 MDA Clinical & Scientific Conference.

Pretzel Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Pretzel Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Pretzel Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWaltham, Massachusetts
Employee Range49
Year Founded2019
Last FundingJul 11, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.